Owned Outcomes

OwnedOutcomes.com

Owned Outcomes (O2) is a software company that helps participating organizations win at various forms of value based care including bundled payments. O2 pinpoints opportunities to episode initiators, engages with physicians around key initiatives and supports patients throughout their episodes to a speedy recovery. We are currently helping providers serve patients in 31 states through 7,500+ physicians representing $8bn+ of medical spend. Bundled payments is a team sport. We facilitate data driven decision making and support across the care continuum to provide high quality outcomes, time and time again.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

NOVAVAX SUBMITS REQUEST TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE

Novavax, Inc. | January 31, 2022

news image

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2. The request for EUA is based on the totality of pre-clinical, clinical and...

Read More

BIOMICA ANNOUNCES THE ADVANCEMENT TO LARGE-SCALE PRODUCTION OF BMC128, ITS LIVE BACTERIAL PRODUCT CANDIDATE CONSORTIUM

Biomica | October 13, 2020

news image

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Read More

MedTech, Industrial Impact

RIBBON BIOLABS REACHES KEY MILESTONE WITH AUTOMATION OF INFINISYNTHTM PLATFORM FOR COMMERCIAL-SCALE, UNLIMITED LENGTH DNA SYNTHESIS

Ribbon Biolabs | December 21, 2022

news image

Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...

Read More

Industrial Impact

SEROTINY AND TESSERA THERAPEUTICS ENTER INTO COLLABORATION TO ENGINEER AND OPTIMIZE PROGRAMMABLE GENE WRITER PROTEINS

Serotiny | March 01, 2022

news image

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins. This collaboration will build on Tessera’s innovations in genome engineering technologies and apply Serotiny’s tMDP mining and design expertise to further optimize Tessera’s programmable G...

Read More
news image

Medical

NOVAVAX SUBMITS REQUEST TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE

Novavax, Inc. | January 31, 2022

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2. The request for EUA is based on the totality of pre-clinical, clinical and...

Read More
news image

BIOMICA ANNOUNCES THE ADVANCEMENT TO LARGE-SCALE PRODUCTION OF BMC128, ITS LIVE BACTERIAL PRODUCT CANDIDATE CONSORTIUM

Biomica | October 13, 2020

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Read More
news image

MedTech, Industrial Impact

RIBBON BIOLABS REACHES KEY MILESTONE WITH AUTOMATION OF INFINISYNTHTM PLATFORM FOR COMMERCIAL-SCALE, UNLIMITED LENGTH DNA SYNTHESIS

Ribbon Biolabs | December 21, 2022

Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...

Read More
news image

Industrial Impact

SEROTINY AND TESSERA THERAPEUTICS ENTER INTO COLLABORATION TO ENGINEER AND OPTIMIZE PROGRAMMABLE GENE WRITER PROTEINS

Serotiny | March 01, 2022

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins. This collaboration will build on Tessera’s innovations in genome engineering technologies and apply Serotiny’s tMDP mining and design expertise to further optimize Tessera’s programmable G...

Read More